Shilpa Medicare has posted strong financial results for Q2 FY25, demonstrating significant growth across key metrics. The company achieved notable improvements in revenue, profitability, and margins, making it a stock to watch in the healthcare sector.
Key Financial Highlights for Q2 FY25 (Consolidated):
- Total Revenue: ₹348.8 crore, up 11% year-over-year (YoY) from ₹314.8 crore in Q2 FY24, and a 16% increase quarter-over-quarter (QoQ) from ₹302.0 crore in Q1 FY25.
- Gross Profit: ₹226.8 crore, reflecting a 20% YoY growth from ₹189.0 crore. Gross profit margin expanded to 65%, up from 60% in the same quarter last year.
- EBITDA: ₹91.0 crore, marking a 46% YoY increase from ₹62.1 crore and a 10% QoQ increase from ₹83.0 crore. The EBITDA margin improved to 26% from 20% in Q2 FY24.
- Net Profit (PAT): ₹18.0 crore, a significant rise of 1008% YoY from ₹1.6 crore, and a 28% QoQ growth from ₹14.1 crore. PAT margin expanded to 5% from 1% in the same period last year.
Summary
Shilpa Medicare’s Q2 FY25 results highlight strong operational performance with substantial growth in profitability. The expansion in EBITDA and PAT margins underscores the company’s improved cost management and operational efficiencies. The healthcare firm’s strategic focus on growth and profitability makes it a compelling stock to monitor in the upcoming quarters.
TOPICS:
Shilpa Medicare